Inclusion Criteria:

- Metastatic renal cell carcinoma with a component of clear cell subtype.

- Prior first line systemic therapy

- At least 1 measurable lesion as per Response Evaluation Criterion in Solid Tumors
[RECIST 1.1].

- Adequate hematology, liver and kidney functions

- Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1.

- Life expectancy of ≥12 weeks.

- Normotensive or well controlled hypertension (less than/equal to 140/90 mm Hg.)

- Negative pregnancy test

- Adequate recovery time from prior systemic therapy, surgery or radiation

- Willing and able subjects who have signed consent

Exclusion Criteria:

- More than one prior systemic therapy regimen

- Major bowel-penetrating surgery <4 weeks

- Active gastro intestinal bleed in past 3 months

- Active peptic ulcer disease in the past 6 months

- Current or anticipated use of potent CYP3A4/5 inhibitors

- Current or anticipated use of known CYP3A4/5 or CYP1A2 inducers

- Requirement for therapeutic warfarin or high dose steroids

- Symptomatic or untreated brain metastases

- A serious uncontrolled medical disorder or active infection

- Pregnant or breastfeeding females

- History of another active malignancy

- Dementia